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We have recently demonstrated a deficiency in the cyclic 
adenosine monophosphate (cAMP) - dependent protein ki-
nases (PKA), the intracellular mediator of AMP, in psoriasis. 
This enzyme defect is expressed in fibroblasts and in red 
blood cells isolated from psoriatic patients. In these cells, the 
abnormality noted in cAMP binding to PKA correlates well 
with the severity of the disease and is corrected by long-term 
treatment with etretinate. In this study, we determined the 
effect of oral administration of acitretin in four psoriatic pa-
tients on the altered cAMP binding observed with the RI 
regulatory subunit of PKA in erythrocytes prepared from 
these patients. Acitretin (30 mg/ day) induced a rapid (within 
1 h) increase in the ability of the RI regulatory subunit of 
erythrocytes to bind the 8-azido[32P]cAMP photoaffinity ana-
logue of cAMP. The maximal plateau for this effect of acitre-
tin was observed within 24 h of treatment and preceded the 
clinical improvement of the disease . The effect of acitretin 
T he etiology of psoriasis remains unclear; however, over the past two decades, a number of pathomechan-isms have been advanced. Among them there is con-siderable evidence to suggest a role for abnormal cy-clic adenosine monophosphate (cAMP) metabolism 
in the manifestation of the disease [1-4]. Recently, we have demon-
strated a deficiency in the cAMP-dependent protein kinases (PKA), 
the intracellular mediator of cAMP, in psoriasis [5]. This enzyme 
defect is expressed in fibroblasts and in red blood cells isolated from 
psoriatic patients. In these cells, t~e abnormal!ty noted i~ cAMP 
binding to PKA correlates well with the seventy of the disease as 
well as its clinical evolution [6]. Of interest is the observation that 
retinoic acid treatment of psoriatic fibroblasts in culture induces an 
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was dose-.dep~ndent, With. t~le m aximal response observed at 
40 mg aCitretm/d. In additIOn, the rapid exposure (15 min) 
of erythro~yt~s Isol~ted. from untreated patients exhibiting 
severe psonaSlS to aCltretm also promoted an increase in bind-
ing .of ~-azi?0[32P]cAM~ to ~he. RI cAMP binding protein. 
RetmolC aCid and 13-ClS-retmOlc acid were as efficient as 
acitretin in inducing the increase in binding of 8-
azido[32P]cAMP to the RI regulatory subunit, whereas aro-
tinoid was without effect. These results suggest that acitretin 
may act to ~~dify PKA (the R~ regulatory subunit) at the 
post-transcnptIOnallevel, and thiS may reflect, in part, on the 
mechanism of action of this synthetic retinoid. Further 
monitoring this biochemical event may be helpful in deter~ 
mining the choice of retinoid therapy and in the manage-
ment of its pharmacology. ] Invest Dermatol 100:77 -81, 
1993 
increase in cAMP - dependent PKA actiVity to levels found in nor-
mal human fibroblasts [7] . 
Retinoic acid derivatives have been used with some success in the 
th~rapeutic t.reatm.ent ?f psoriasis. Etretinate. and more recently its 
aCid metabolite, aCltr~tln, ~re. the ~o synthetiC retinoids that appear 
to be the most effective c1ullcally III the treatment of psoriasis (see 
for r.e~iew [8]). We previo~sly s~owed .in .a long-term study that 
admlllistration of oral etretlllate III psortatlc patients resulted in a 
correction in the defective binding of 8-azido-[J2P]cAMP to the RI 
~egulatory subunits of .PKA observed in s~dies with erythrocytes 
Isolated from these patients [5]. Therefore It was of interest to fur-
ther characterize this effect of retinoid derivatives on the abnormal 
cAMP binding found in ps?riat~c eryth~ocytes. In this study, we 
?emonstrate that ~ral a~m~mstrat~on of aCI.tretin to psoriatic patients 
1I1duces a very ra~ld (wlth1l1 1 h) 1I1creaSe 111 the capability of the RI 
regulatory subumt ~f erythrocytes to bind the 8-azido-[J2P]cAMP 
analogue of cAMP 111 a dose-dependent manner. In addition the 
r~p~d. exposure of erytl:rocyt~s isolated ~rom untreated patient~ ex-
hibiting severe psonasls to aCltret1l1, retlnoic acid, and 13-cis-retin-
oic acid also promotes an increase in binding of this cAMP analogue 
to the RI cAMP binding protein. 
MATERIALS AND METHODS 
Subjects. Thirteen patients with psoriasis vulgaris were studied. 
The seventy of the disease was evaluated by the Psoriatic Area and 
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Table I. Clinical and Biochemical Characteristics of the 
Patients Studied 
Patient 
Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Gende!"'/ 
Age (years) 
M/31 
M/40 
M/54 
M/59 
M/80 
M/55 
F/20 
F/64 
F/57 
M/52 
M/52 
M/22 
M/45 
• M, male; F, female. 
PASl 
Score 
19.0 
22 .8 
12.8 
30.9 
13.8 
42.4 
25 .3 
20.0 
16.5 
5.7 
7.2 
10.2 
24 .3 
8-Azido-[32P) 
cAMP Boundb 
(fmol/J.lg membrane 
protein) 
510 
408 
582 
385 
550 
210 
532 
478 
490 
752 
615 
689 
380 
I Photoaffinity labeling with 8-azido-[32P]cAMP of the RI regulatory subunit in 
erythrocyte membranes of the patients analyzed, as described in Malerials and Meth-
ods. 
Severity Index (PASI score), as previously defined [5]. These pa-
tients had received no specific treatment; no systemic therapy, such 
as corticosteroids, antimitotic drugs, or retinoids, for at least 1 year 
prior to this study; no non-steroidal anti-inflammatory drugs for at 
leas t 2 weeks prior to the assay; and no local corticosteroids, ultra VIO-
let light, or oraJ or topical psoralene for at least 3 months prior to the 
assay. Subjects took part in this study only after they had given 
informed consent to the protocol approved by the Ethical Commit-
tee of Hospital Cochin Port Royal. 
Oral Acitretin Treatment Acitretin was administered as a sin-
gle dose ; as indicated, per day following a continental breakfast. 
In Vitro Retinoid Treatment Thirty milliliters of blood were 
drawn in heparinized tubes. The blood sample was centrifuged at 
1000 X g for 10 min at room temperature. The upper ring of white 
cells was carefully removed, and the erythrocyte pellet was resus-
pended with one-third its volume of plasma from the subject. The 
resuspended erythrocytes were incubated for the indicated time in 
the presence and absence of 1 or 0.1 ,uM of acitretin, retinoic acid, 
13-cis-retinoic acid, or arotinoid, as indicated at 4°C, and treated 
erythrocytes were recovered from the incubation mixture by centrif-
ugation at 1000 Xg for 10 min at 4°C. All further steps were 
carried out at 4 ° C. 
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Preparation of Erythrocyte Membranes Erythrocyte memo 
branes were prepared according to a modification of the procedure 
of Dodge et at [9]. A 10-ml sample of heparinized blood was ob-
tained and immediately centrifugated for 30 min at 1000 X g at 
4°C. The erythrocyte pellet obtained was suspended in 10 ml of 
0.172 M Tris-HCl (pH 7.6) and washed three times with 10 ml of 
this buffer. The washed erythrocytes then were lysed by suspension 
in six volumes of hypotonic 0.011 M Tris-HCI (pH 7.6), and eryth-
rocyte membranes were isolated by centrifugation at 2000 X g for 
40 min. The membrane pellet was washed three times with 
0.011 M Tris-HCI (pH 7.6) solubilized by resuspension in 1 % NP-
40 detergent for 5 min at 4 ° C and then stored frozen at - 80 0 e 
until used for assay. 
Photoaflinity Labeling with 8-Azido(l2P]cAMP RI regula-
tory subunits were photoafiinity labeled as described by Walter et al 
[10] in a reaction mixture (80 ,ul) containing 10 mM 2[N-morpho-
lino]ethane sulfonic acid (MES), pH 6.2/10 mM MgCld1.0 mM 
8-azido-[32P]cAMP, along with 100,ug of crude red cell membrane 
protein. Where indicated, lOO.uM cAMP was included to block 
8-azido-(32P]cAMP binding to determine non-specific labeling. 
Mixtures were incubated for 60 min in the dark at 4 ° C and thell 
irradiated for 10 min with an ultraviolet lamp to allow irreversible 
photoaffinity binding of 8-azido-(32PJcAMP to the RI subunit. The 
irradiated samples were pipetted into 20 ml of stop solution [9% 
sodium dodecyl sulfate (SDS) 15% (v/v) glycerol/6 mM ethylene-
diaminetetraacetic acid (EDTA)/250 mM Tris-HCI, pH 8] and 
heated at 100° C for 20 seconds. Then, 2,u1 of 2-mercaptoethanol 
and S,ul of 0.1 % bromophenol blue in 50% (v Iv) glycerol were 
added, and the samples were electrophoresed in 10% polyacrylam-
ide slab gels containing SDS. The gels were dried and autoradio-
graphed at -80°C using Cronex 4 Dupont medical X-ray film. 
The autoradiographs were quantitated by scanning with a micro-
densitometer. One hundred micrograms of protein labeled with 
8-azido-[3ZP]cAMP were applied to each gel lane to allow compari-
son among the different lanes and autoradiographs. When care was 
taken not to overexpose the X-ray film, the peak heights obtained 
by scanning were proportional to the total radioactivity of the 
co~responding peaks estimated by scintillation counting, as de-
scnbed by Walter et at [10]. Levels ofRI regulatory subunit were 
calculated by integrating the areas under the curves and subtracting 
non-specific labeling noted in the presence of 100,uM cAMP. De-
tenn!nations for each subject were carried out in duplicate, and 
duphcates were found to agree within ± 10%. 
Protein Determination Protein concentrations are determined 
by fluorometric assay [11], with bovine serum albumin as the stan-
dard. 
Table II. Time-Course of the Effect of Oral Administration of Acitretin in Four Psoriatic Patients on the Binding 
of 8-Azido-[32P]cAMP to the RI Subunit Present in Erythrocytes 
Time-Course 
Patient 1 Hour 1 Day 8 Days 15 Days 1 Month 
8-Azido-[32PJcAMP 1090 954 1818 1009 binding" 
PASI score 19.0 17.0 12.9 l2.2 9.0 2 8-Azido-[32P)cAMP 160 368 362 417 316 binding" 
PASI score 22.8 22.0 18.0 15.0 6.5 3 8-Azido-[32P)cAMP 349 737 419 1357 1130 binding" 
PASI score 12.8 12.0 9.0 5.0 3.0 13 8-Azido-[32P)cAMP 268 152 350 binding" 
PASI score 24.3 19.0 5.0 
• Percent of the value determined at the beginning of the treatment (see Table I). 
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Figure 1. Effect of increasing doses of orally administered acitretin to a 
psoriatic subject on the binding of the cAMP analogue 8-azido-[32P]cAMP 
to the RI regulatory subunit present in erythrocyte membranes isolated 
from the patient. A) Autoradiographs showing the photoactivated incor-
poration of 8-azido-[32P]cAMP into the RI regulatory subunit analyzed by 
50S polyacrylamide gel electrophoresis in erythrocytes prepared from 
patient 4. B) Quantitation of the amount of 8-azido-[32P]cAMP incorpo-
ra ted into the RI regulatory subunit was carried out as described in Materi-
als alld Methods. Results are expressed as mean ± SO of the percent of 
untreated control values in three psoriatic patients (patients 4,5, and 13). 
The psoriatic patients first were administered 10 mg of acitretin every 
24 h for 7 d, and erythrocytes then were prepared from blood drawn on 
the eighth day. This was immediately followed by a similar regimen of 
treatment for 7 d with 20 mg of acitretin, followed by 30 mg of acitretin 
for 7 d, and finally 7 d of treatment with 40 mg of acitretin. 
RESULTS 
As shown in Table 1,13 patients with severe psoriasis as evaluated by 
the PAS! score were used as subjects in this work. Erythrocyte 
membranes prepared from erythrocytes obtained from these pa-
t ients all exhibited decreased binding of 8-azido-(32P]cAMP to the 
RI regulatory subunit compared with normal subjects (normal 
values of8-azido-[32P]cAMP photoaffinity labeling of the RI regula-
tory subunit are 930 ± 35 fmol 8-azido-[32P]cAMP bound/ l00 I1g 
erythrocyte membrane protein [6]) . 
The time-course of the effect of oral acitretin treatment on the 
binding of the photoaffinity cAMP ana logue to the erythrocyte 
membrane RI regulatory subunit was studied in four of the psoriatic 
patients (Table II). Oral acitretin treatment (30 mg/d) produced a 
significant increase in the amount of specific binding of 8-azido-
(32P]cAMP to the RI regulatory subunit of PKA in erythrocyte 
membranes. Interestingly, this increase occurred very rapid ly and 
was clearly observed within 1 h of acitretin treatment in three of the 
patients. The plateau of the effect of acitretin was obtained 24 h 
after the first ingestion of the retinoid and preceded the clinical 
improvement in the disease (within 8 d), as noted by the PASI score 
(Table II) . 
The capability of acitretin to induce normal binding of the cAMP 
analogue to the R! regulatory subunit in red blood cell membranes 
prepared from treated psoriatic patients was dose-dependent (Fig 1). 
In psoriatic patient 4, the maximal effect was observed with the oral 
administration of 40 mg of acitretin (Fig lA). As shown in Fig IB , 
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increasing doses of acitretin treatment from 10 to 40 mg/d in three 
psoriatic patients (patients 4, 5, and 13) induced a progressive in-
crease in 8-azido-[32P]cAMP binding to the RI regulatory subunit to 
a maximum of323 ± 59% (mean ± SD) of the value observed prior 
to the onset of treatment. The interruption of acitretin treatment for 
8 d. (after 2 weeks of acitre tin treatment at 40 mg/d), in psoriatic 
patient 4 resulted 111 a reversal of the effect to again exhibit the 
decreased levels of 8-azido-(32P]cAMP binding to the RI regulatory 
subulllt (a decrease from 1059 to 153 fmol 8-azido-[32P]cAMP 
bound/l~O .l1g erythrocyte membrane protein). This level was 
c.haractenstic of .erythrocytes prepared from severely psoriatic pa-
t1~nts prIor to aCItret1l1 treatment; however, a short interruption in 
acltre~l?, treatment (for 2 days) induced only a 40% decrease in the 
capablhty of the RI regulatory subunit to bind the cAMP analogue 
(preliminary data not shown). 
This very rapid)effect of orally administered acitretin on the regu-
latory subulllt of! KA 111 red blood cells led us to determine w hether 
acitretin m~ght have a similar ~ffect ill lIitro on isolated erythrocytes. 
As shown 111 Tabl~ III, ac~tret1l1 treatment of isolated erythrocytes 
?bta1l1ed .from patients w31;h severe psoriasis induced a significant 
1I1crease 111 the 8-azldo~[ ~]cAMP binding to the RI regulatory 
subu.l1lt. In contrast, no s l gl1l~cant effect of acitretin on erythrocytes 
obta1l1ed from normal subject was observed on the 8-azido-
[32P]cAMP binding to the RI subunit in normal red blood cells. This 
in vitro e.ffect of ac~tretin. on psori~tic ery~hrocytes was dose-depen-
dent, With a maxllnal 1I1crease 111 b1l1dmg observed with 10-8-
10- 7 M of acitretin (Fig 2). Retinoic acid and 13-cis-retinoic acid 
were as effective as acitretin in increasing the binding of 8-azido-
[32P]cAMP to the RI regul atory subunit, w hereas arotinoid was 
ineffective (Table III) . Again, no il'l viero effect of these retinoids was 
observed on RI binding with erythrocytes from normal subjects . 
DISCUSSIO N 
Previous studies have established a close relationship between reti-
noic. acid and cAMP to mediate a nu~~er of biologic responses, 
partIcularly cell growth. and differentiatIOn. Many cell types, in-
cludl\1g myelOid leukemia, teratocarCll1oma, melanoma, and kidney 
ce.lls, are responsive to this treatment (for review, see [1 2]) . In psori-
atIc fibroblasts, sequential exposure to retmoic acid and then to 
8-Br-cAMP induces a decrease in cell growth, whereas 8-Br-cAMP 
alone is only marginally effective in decreasing psoriatic fibroblast 
growth [13] . This treatment with re tin?ic acid may induce changes 
that alter the response to cAMP, a.nd eVidence 1Il different cell types 
suggests that changes m PKA actiVity may be one of the targets of 
retinoic acid actio?, [14 - 17] . I?,deed, PKA appear to be largely, if 
not solely, responSible for carrymg out the biologic effects of cAMP. 
There are two major forms of PKA (types I and II). These forms 
differ in the nature of their cAMP binding regulatory subunits (RI 
and RIl). Human erythrocyte membranes contain RI but not RII 
[1 8,19]. 
W e have demonstrated in psoriatic cells that there is a defect in 
the PKA expressed not only in fibrobl asts, but also in red blood cells. 
The capacity of the regulatory subunits to bind cAMP and its ana-
logue, 8-azido[32P]cAMP, seems to be abnormal in erythrocytes 
isolated from psoriatic patients [6]. 
Retinoid treaunent of psoriatic fibroblasts in culture induces an 
increase in cAMP-~ependel1t PKA activity [7] . In addition, we have 
shown tl~at system~c treatmen~ of psoriatic patients with etretinate 
resulted ll1 a reverSIOn of the blllding defect of the cAMP analogue 
8-azi?0[32P]cAMP to the PKA .toward normal level [6]. 
A.cltretll1 ~s the aCid metaboltte of etretinate. Both of these aro-
ma.tlc r~tmOids belong t.o the second-generation family of retinoids. 
~cltretll1 ?~ers tl~ e chmcal a~vant~ge ~f not being stored in adipose 
t~ssue . Chmcal tnals eva l~latlllg aCltret111 111 the treatment of psoria-
SIS parallel the l11ve~tlgatIOn. of etretl11ate [20]. III lI itro experiments 
demonstrate that aCltretl11, hke etretinate, can influence the chemo-
taxis of gr~nulocytes, inhibit the proliferative response of lympho-
cytes to mltogens, and lllfluence keratine synthesis in culture. In this 
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Table III. In Vitro Effect of Retinoids on the Level of 8-Azido[32P]cAMP Specifically bound to the RI Regulatory Subunit of 
cAMP-Dependent Protein Kinase Present in the Membrane Fraction of Red Blood Cells· 
Retinoid 
8-Azido[32P)cAMP Binding (% of Untreated Control) 
Concentration + 13-cis-
Patient Number or Letter (uM) + Retinoic Acid + Acitretin Retinoic Acid + Arotinoid 
Psoriatic patients 
5 1 140 152 149 110 
8 1 120 139 130 100 
6 1 153 
9 1 150 
10 0.1 154 151 150 109 
11 0.1 130 148 134 96 
12 0.1 155 161 154 105 
Normal subjects 
A 1 103 
B 1 100 110 107 98 
C 1 109 
D 1 100 103 101 97 
E 0.1 100 100 102 100 
F 0.1 100 101 102 96 
• Erythrocytes were treated ill vitro for 15 min with either 0.1 or 1 JIM of retinoic acid, acitretin, 13-cis-retinoic acid, Or arotinoid. Then, erythrocyte membranes were prepared, 
and photoaffinity labeling with 8-azido-I32PJcAMP was carried out, as described in Materials alld Methods. The binding of 8-azido-[32PJcAMP to the RI regulatory subunit was 
analyzed by SDS polyacrylamide gel electrophoresis. The amount of ["PI bound was quantitated by cutting the radioactive band from the gel and determining the amount of 
radioactivity present in the solubilized band with a scintillation counter. Results are expressed as percent of the control value listed in Table I. 
study, we show that acitretin treatment, as well as etretinate treat-
ment [6], can correct the binding defect ofPKA in psoriatic patients. 
Our previous study with long-term treatment with etretinate [6] 
did not allow us to determine whether the observed enhancement in 
photoaffll1ity labeling of RI by 8-azido(3zP]cAMP was directly re-
lated to the retinoid treatment or, less specifically, to an improve-
ment in the disease state. In this study, we clearly demonstrate that 
retinoid treatment (i .e., the oral intake of acitretin) very rapidly 
(within 1 h) corrects the low binding noted in erythrocytes from 
untreated psoriatic patients. This effect of orally administered aci-
tretin is dose dependent. These data suggest a direct and immediate 
effect of acitretin on the PKA or erythrocytes of the psoriatic pa-
tients. This is further suggested by preliminary data obtained in one 
psoriatic subject. Interruption of treatment with acitretin for an 
interval of time (8 d) that is greater than the elimination half-life of 
acitretin (50 h), is followed by the reappearance of the binding 
defect observed with the RI subunit of psoriatic erythrocytes. In 
contrast, a short interruption of acitretin treatment « 48 h) allows 
only a small decrease in binding of the cAMP analogue toward that 
noted with cells from untreated psoriatic patients. 
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Figure 2. Effect of treatment of isolated psoriatic erythrocytes for 15 min 
with increasing concentrations of acitretin on the binding of 8-azido-
[32PJcAMP to the RI regulatory subunit. The amount of the 8-azido-
[l'P]cAMP photoaffinity analogue bound to the RI regulatory subunit 
following treatment of the isolated erythrocytes with the indicated con-
centrations of acitretin for 15 min was determined by SDS polyacrylam-
ide gel electrophoresis followed by autoradiography, as described in Mate-
rials and Methods. 
The mechanisms responsible for the effects of retinoic acid and its 
synthetic derivatives have not been fully elucidated. An important 
insight has been provided by the discovery of three retinoic acid 
receptors (a, p, y). The retinoic acid receptors are believed to func-
tion in a manner analogous to other members of the steroid/thyroid 
hormone receptor family with which they have a high degree of 
sequence similarity [21-25]. Retinoic acid receptor-y is reported to 
be ~he type ~xpressed in the skin [26]; however, the mechanism of 
actlOn of retlnOlds to modulate cAMP-dependent PKA remains to 
be elucidated. Retinoid treatment of psoriatic cells may induce an 
elevation ofPKA activity either by increasing PKA protein levels or 
by inducing a modification of the enzyme to influence cAMP bind-
ing and phosphotransferase activity. As shown in this study, the 
effect of orally administered acitretin to increase the binding of 
8-azido-(3zP}cAMP to the RI cAMP binding regulatory subunit of 
PKA is very rapid . A similar response is observed with ill vitro treat-
ment of isolated psoriatic erythrocytes with acitretin. This ill vitro 
effect is observed within minutes and occurs in anucleated cells. 
These data suggest that acitretin acts to modify the cAMP-depen-
dent PKA at a post-transcriptionalleve!. 
In this regard, retinoylation (retinoic acid acylation) is a covalent 
modification of specific proteins that occurs in a variety of eukary-
otic cell lines [27] . Recently, it was reported that both the RI and RII 
reg~latory subunits of PKA appear to be retinoylated [28]. Studies 
are In progress to determ1l1e whether retinoylation of RI and RII 
occurs in psoriatic cells and whether this type of modification might 
alter th.e binding of 8-azido(32P]cAMP to the regulatory subunits. 
PrevlOusly, weshowe~ that long-term treatment of psoriatic fi-
broblasts With retlnOIC aCid and With other retinoids, such as 13-cis-
retinoic ~c~d and arotinoid, resulted in increased cAMP-dependent 
PKA actlVlty [7]. In the present study, rapid (15 min) treatment of 
~nucleated erythrocytes with arotinoid had no effect on the capabil-
Ity of the RI regulatory subunit to bind the cAMP analogue, 
whereas the ot~er .retlnOlds tes~ed were effective. The discrepancy 
betw~en these /fJ vl./ro results WIth arotenoid might be explained by 
the ~Ifferent experu~ental conditions used. These results suggest a 
pOSSIble dual regulatIOn of PKA with a rapid effect related to post-
transcriptional modification of the enzyme and a more long-term 
effect related to altered gene expression. 
Th.e ease in ~btaining erythrocytes from patients and the presence 
of tillS defect m cAMP-dependent PKA in erythrocytes obtained 
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fro m psoriatic patients prese.nt a useful c.ell popula.ti~n t? determine 
the presence and the evolu~lOn of the disease. TIllS /tI vItro effect of 
retinoids on PKA 111 psonatlc erythrocytes ma.y reflect on the I~ec.ha­
nism and efficacy for the in vivo therapeutic ~ffects .of. ret1l10lds. 
Thus, initial studies on the retinoid effect on ~I 111 psoriatic erythro-
cytes may be helpful in determining the chOIce of therapy and the 
management of its pharmacology. 
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